LAUSR

Breast cancer accounts for more than one million new cases annually and is the leading cause of death in women globally. HER2 overexpression induces cellular and humoral immune responses against the HER2 protein and is associated with higher tumor proliferation rates. Trastuzumab‐based therapies are effectively and widely used as standard of care in HER2‐amplified/overexpressed breast cancer patients; one cited mechanism of action is the induction of passive immunity and antibody‐dependent cellular cytotoxicity against malignant breast cancer cells. These findings drove the efforts to generate antigen‐specific immunotherapy to trigger the patient's immune system to target HER2‐overexpressing tumor cells, which led to the development of various vaccines against the HER2 antigen. This article discusses the various anti‐HER2 vaccine formulations and strategies and their potential role in the metastatic and adjuvant settings.